These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 22360684

  • 1. Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer.
    Leblanc AK, Miller AN, Galyon GD, Moyers TD, Long MJ, Stuckey AC, Wall JS, Morandi F.
    Vet Radiol Ultrasound; 2012; 53(3):348-57. PubMed ID: 22360684
    [Abstract] [Full Text] [Related]

  • 2. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA, Hannah AL, Zadovoskaya R, Chien MB, Kollias-Baker C, Rosenberg M, Downing S, Post G, Boucher J, Shenoy N, Mendel DB, McMahon G, Cherrington JM.
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [Abstract] [Full Text] [Related]

  • 3. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, Bergman PJ, Couto GC, Mauldin GN, Michels GM.
    Clin Cancer Res; 2009 Jun 01; 15(11):3856-65. PubMed ID: 19470739
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic properties of toceranib phosphate (Palladia, SU11654), a novel tyrosine kinase inhibitor, in laboratory dogs and dogs with mast cell tumors.
    Yancey MF, Merritt DA, Lesman SP, Boucher JF, Michels GM.
    J Vet Pharmacol Ther; 2010 Apr 01; 33(2):162-71. PubMed ID: 20444041
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours.
    London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, Ettinger S, Vaughan A, Alvarez F, Hillman L, Kiselow M, Thamm D, Higginbotham ML, Gauthier M, Krick E, Phillips B, Ladue T, Jones P, Bryan J, Gill V, Novasad A, Fulton L, Carreras J, McNeill C, Henry C, Gillings S.
    Vet Comp Oncol; 2012 Sep 01; 10(3):194-205. PubMed ID: 22236194
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
    Tani H, Miyamoto R, Noguchi S, Kurita S, Nagashima T, Michishita M, Yayoshi N, Tamura K, Bonkobara M.
    BMC Vet Res; 2021 Apr 07; 17(1):147. PubMed ID: 33827546
    [Abstract] [Full Text] [Related]

  • 11. Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
    Prior JO, Montemurro M, Orcurto MV, Michielin O, Luthi F, Benhattar J, Guillou L, Elsig V, Stupp R, Delaloye AB, Leyvraz S.
    J Clin Oncol; 2009 Jan 20; 27(3):439-45. PubMed ID: 19064982
    [Abstract] [Full Text] [Related]

  • 12. Assessment of tumor enhancement by contrast-enhanced CT in solid tumor-bearing dogs treated with toceranib phosphate.
    Takagi S, Yamazaki H, Izumi Y, Hanazono K, Hoshino Y, Hosoya K.
    Vet Radiol Ultrasound; 2020 Jul 20; 61(4):427-434. PubMed ID: 32162400
    [Abstract] [Full Text] [Related]

  • 13. 18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
    Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindié E, Moretti JL.
    Cancer Biother Radiopharm; 2009 Feb 20; 24(1):137-44. PubMed ID: 19243256
    [Abstract] [Full Text] [Related]

  • 14. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP, Johannes CM, Jergens AE, Allenspach K, Powers BE, Du Y, Mochel JP, Fox LE, Musser ML.
    J Vet Intern Med; 2018 Nov 20; 32(6):2045-2053. PubMed ID: 30307656
    [Abstract] [Full Text] [Related]

  • 15. Toceranib phosphate (Palladia) for the treatment of canine exocrine pancreatic adenocarcinoma.
    Musser ML, Johannes CM.
    BMC Vet Res; 2021 Aug 11; 17(1):269. PubMed ID: 34380474
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018.
    Lew FH, McQuown B, Borrego J, Cunningham S, Burgess KE.
    Vet Comp Oncol; 2019 Dec 11; 17(4):465-471. PubMed ID: 31069932
    [Abstract] [Full Text] [Related]

  • 18. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
    Yamazaki H, Miura N, Lai YC, Takahashi M, Goto-Koshino Y, Yasuyuki M, Nakaichi M, Tsujimoto H, Setoguchi A, Endo Y.
    J Vet Med Sci; 2017 Jul 19; 79(7):1225-1229. PubMed ID: 28592719
    [Abstract] [Full Text] [Related]

  • 19. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
    Hansen AE, Kristensen AT, Law I, McEvoy FJ, Kjær A, Engelholm SA.
    Radiother Oncol; 2012 Mar 19; 102(3):424-8. PubMed ID: 22119225
    [Abstract] [Full Text] [Related]

  • 20. Safety evaluation of combination doxorubicin and toceranib phosphate (Palladia®) in tumour bearing dogs: a phase I dose-finding study.
    Pellin MA, Wouda RM, Robinson K, Tsimbas K, Kurzman ID, Biller BJ, Vail DM.
    Vet Comp Oncol; 2017 Sep 19; 15(3):919-931. PubMed ID: 27146577
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.